Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity

被引:538
作者
Ogitani, Yusuke [1 ]
Hagihara, Katsunobu [2 ]
Oitate, Masataka [2 ]
Naito, Hiroyuki [3 ]
Agatsuma, Toshinori [1 ]
机构
[1] Daiichi Sankyo Co Ltd, Biol & Immunooncol Labs, Tokyo, Japan
[2] Daiichi Sankyo Co Ltd, Drug Metab & Pharmacokinet Res Labs, Tokyo, Japan
[3] Daiichi Sankyo Co Ltd, Oncol Labs, Tokyo, Japan
关键词
Antibody-drug conjugate; bystander killing; HER2; T-DM; topoisomerase I inhibitor; BRENTUXIMAB VEDOTIN; GEMTUZUMAB OZOGAMICIN; TRASTUZUMAB EMTANSINE; CATHEPSIN-B; EXPRESSION; LYMPHOMA; THERAPY; PHASE-3; SAFETY;
D O I
10.1111/cas.12966
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Antibody-drug conjugates deliver anticancer agents selectively and efficiently to tumor tissue and have significant antitumor efficacy with a wide therapeutic window. DS-8201a is a human epidermal growth factor receptor 2 (HER2)-targeting antibody-drug conjugate prepared using a novel linker-payload system with a potent topoisomerase I inhibitor, exatecan derivative (DX-8951 derivative, DXd). It was effective against trastuzumab emtansine (T-DM1)-insensitive patient-derived xenograft models with both high and low HER2 expression. In this study, the bystander killing effect of DS-8201a was evaluated and compared with that of T-DM1. We confirmed that the payload of DS-8201a, DXd (1), was highly membrane-permeable whereas that of T-DM1, Lys-SMCC-DM1, had a low level of permeability. Under a coculture condition of HER2-positive KPL-4 cells and negative MDA-MB-468 cells in vitro, DS-8201a killed both cells, whereas T-DM1 and an antibody-drug conjugate with a low permeable payload, anti-HER2-DXd (2), did not. In vivo evaluation was carried out using mice inoculated with a mixture of HER2-positive NCI-N87 cells and HER2-negative MDA-MB-468-Luc cells by using an in vivo imaging system. In vivo, DS-8201a reduced the luciferase signal of the mice, indicating suppression of the MDA-MB-468-Luc population; however, T-DM1 and anti-HER2-DXd (2) did not. Furthermore, it was confirmed that DS-8201a was not effective against MDA-MB-468-Luc tumors inoculated at the opposite side of the NCI-N87 tumor, suggesting that the bystander killing effect of DS-8201a is observed only in cells neighboring HER2-positive cells, indicating low concern in terms of systemic toxicity. These results indicated that DS-8201a has a potent bystander effect due to a highly membrane-permeable payload and is beneficial in treating tumors with HER2 heterogeneity that are unresponsive to T-DM1.
引用
收藏
页码:1039 / 1046
页数:8
相关论文
共 27 条
[1]   Cathepsin B: Multiple roles in cancer [J].
Aggarwal, Neha ;
Sloane, Bonnie F. .
PROTEOMICS CLINICAL APPLICATIONS, 2014, 8 (5-6) :427-437
[2]   Detecting intratumoral heterogeneity in routine breast-HER2 testing: low yield of testing multiple blocks [J].
Bethune, Gillian C. ;
Mullen, J. Brendan ;
Chang, Martin C. .
ANNALS OF DIAGNOSTIC PATHOLOGY, 2015, 19 (06) :385-390
[3]  
Bross PF, 2001, CLIN CANCER RES, V7, P1490
[4]   Phase II Study of the Antibody Drug Conjugate Trastuzumab-DM1 for the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2) -Positive Breast Cancer After Prior HER2-Directed Therapy [J].
Burris, Howard A., III ;
Rugo, Hope S. ;
Vukelja, Svetislava J. ;
Vogel, Charles L. ;
Borson, Rachel A. ;
Limentani, Steven ;
Tan-Chiu, Elizabeth ;
Krop, Ian E. ;
Michaelson, Richard A. ;
Girish, Sandhya ;
Amler, Lukas ;
Zheng, Maoxia ;
Chu, Yu-Waye ;
Klencke, Barbara ;
O'Shaughnessy, Joyce A. .
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (04) :398-405
[5]   The Effect of Different Linkers on Target Cell Catabolism and Pharmacokinetics/Pharmacodynamics of Trastuzumab Maytansinoid Conjugates [J].
Erickson, Hans K. ;
Phillips, Gail D. Lewis ;
Leipold, Douglas D. ;
Provenzano, Carmela A. ;
Mai, Elaine ;
Johnson, Holly A. ;
Gunter, Bert ;
Audette, Charlene A. ;
Gupta, Manish ;
Pinkas, Jan ;
Tibbitts, Jay .
MOLECULAR CANCER THERAPEUTICS, 2012, 11 (05) :1133-1142
[6]   cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity [J].
Francisco, JA ;
Cerveny, CG ;
Meyer, DL ;
Mixan, BJ ;
Klussman, K ;
Chace, DF ;
Rejniak, SX ;
Gordon, KA ;
DeBlanc, R ;
Toki, BE ;
Law, CL ;
Doronina, SO ;
Siegall, CB ;
Senter, PD ;
Wahl, AF .
BLOOD, 2003, 102 (04) :1458-1465
[7]   Anetumab Ravtansine: A Novel Mesothelin-Targeting Antibody-Drug Conjugate Cures Tumors with Heterogeneous Target Expression Favored by Bystander Effect [J].
Golfier, Sven ;
Kopitz, Charlotte ;
Kahnert, Antje ;
Heisler, Iring ;
Schatz, Christoph A. ;
Stelte-Ludwig, Beatrix ;
Mayer-Bartschmid, Anke ;
Unterschemmann, Kerstin ;
Bruder, Sandra ;
Linden, Lars ;
Harrenga, Axel ;
Hauff, Peter ;
Scholle, Frank-Detlef ;
Mueller-Tiemann, Beate ;
Kreft, Bertolt ;
Ziegelbauer, Karl .
MOLECULAR CANCER THERAPEUTICS, 2014, 13 (06) :1537-1548
[8]   Safety and efficacy of brentuximab vedotin for Hodgkin lymphoma recurring after allogeneic stem cell transplantation [J].
Gopal, Ajay K. ;
Ramchandren, Radhakrishnan ;
O'Connor, Owen A. ;
Berryman, Robert B. ;
Advani, Ranjana H. ;
Chen, Robert ;
Smith, Scott E. ;
Cooper, Maureen ;
Rothe, Achim ;
Matous, Jeffrey V. ;
Grove, Laurie E. ;
Zain, Jasmine .
BLOOD, 2012, 120 (03) :560-568
[9]   Antibody-drug conjugates for cancer therapy: The technological and regulatory challenges of developing drug-biologic hybrids [J].
Hamilton, Gregory S. .
BIOLOGICALS, 2015, 43 (05) :318-332
[10]   Antibody Drug Conjugates: Nonclinical Safety Considerations [J].
Hinrichs, Mary Jane Masson ;
Dixit, Rakesh .
AAPS JOURNAL, 2015, 17 (05) :1055-1064